T2EVOLVE

Accelerating development and improving access to CAR and TCR-engineered T cell therapy
T2Evolve logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 18
Grant agreement number
945393

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
8 728 185
EFPIA in kind
7 771 500
Associated Partners
2 575 000
Total Cost
19 074 685

Summary

T cells are an important part of the immune system, and in recent years scientists have succeeded in creating ‘engineered’ T cells designed specifically to seek out and destroy cancer cells. Scientists are working on a number of cancer treatments based on T cells, but their efforts are hampered by a number of challenges. Firstly, when developing a T cell therapy, it is very hard to predict if it will be safe and how well it will work. Secondly, their manufacture at scale is extremely complicated.

The aim of T2EVOLVE is to develop an innovation ecosystem that will accelerate the development of engineered T cell therapies in the EU.

Among other things, it will do this by delivering tools and markers that will improve our ability to predict the toxicity and efficacy of T cell therapies, as well as techniques to analyse the behaviour of T cells in the body. The team also plans to develop standardised methods for producing T cell therapies and monitoring them during treatment.

Another goal is to integrate patients more fully into all aspects of T cell research and development, and to deliver tools for education to improve communication between healthcare providers and patients.

Finally, the project will address questions on patient access to T cell therapies by issuing recommendations on how to ensure broad patient access to T cell therapies, and how they could be made more affordable.

Participants Show participants on map

EFPIA companies
  • Astellas Pharma Europe BV, Leiden, Netherlands
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Celgene Management SARL, Couvet, Switzerland
  • Institut De Recherches Internationales Servier Iris, Suresnes, France
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland
Universities, research organisations, public bodies, non-profit groups
  • Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands
  • Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel, Langen, Germany
  • Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Barcelona, Spain
  • Erasmus Universiteit Rotterdam, Rotterdam, Netherlands
  • Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany
  • Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau Fundacion, Barcelona, Spain
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • Institut National Du Cancer Gip, Boulogne Billancourt, France
  • Medizinische Universitaet Wien, Vienna, Austria
  • Ospedale Pediatrico Bambino Gesu, Rome, Italy
  • Technische Universitaet Muenchen, Muenchen, Germany
  • Universidad De Navarra, Pamplona, Spain
  • Universita Vita-Salute San Raffaele, Milano, Italy
  • Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat, Wuerzburg, Germany
  • University College London, London, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Biosci Consulting Bvba, Maasmechelen, Belgium
  • Information Technology For Translational Medicine (Ittm) SA, Esch-sur-Alzette, Luxembourg
  • Miltenyi Biotec BV & Co Kg, Bergisch Gladbach, Germany
  • T-Curx GMBH, Wurzburg, Germany
Patient organisations
  • European Cancer Patient Coalition, Brussels, Belgium
Associated partners
  • European Hematology Association, The Hague, Netherlands
Third parties
  • Hospital Clinic De Barcelona, Barcelona, Spain
  • Stichting Vumc, Amsterdam, Netherlands
Project coordinator
Michael Hudecek
Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat